Navigation Links
Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
Date:10/1/2007

A sustained viral response was achieved by significantly more patients who received a weight-based dose (44.2 percent) than fixed dose (40.5 percent) ribavirin, the authors report. Overall, response rates decreased as weight increased when a fixed dose was used but remained unaltered with a weight-based dose. Discontinuation rates and reported adverse events did not differ significantly between the two treatment schemes, and relapse rates were lower for patients who had received weight-based dosing. The researchers also found that 48 weeks of treatment offered no additional benefit compared to 24 weeks for patients with genotypes 2 or 3..

Another group of researchers from the same study, also lead by Jacobson, used the study data to understand the impact of weight-based ribavirin with peginterferon alfa-2b in African American patients with HCV genotype 1. Genotype 1 is the hardest to treat, and it afflicts African Americans disproportionately.

Three hundred eighty seven African American patients with genotype 1 were included in the analysis: of those weighing 65 kg or more, and therefore receiving different doses of ribavirin in each arm, 188 had received flat-dose ribavirin, and 174 had received weight-based dosing. Significantly fewer patients in the flat-dose group (10 percent) attained a sustained virological response, compared to 21 percent in the flat-dose group. Relapse rates were 30 percent and 22 percent, respectively.

An unexpected finding of our study was the increase in efficacy with an increase in ribavirin dose in heavier patients, the authors report. That is, sustained viral response rates increased as body weight increased, suggesting that ribavirin distribution may be more complex than realized and body weight may only approximate the marker for size required to dose RBV consistently, the authors say.

In conclusion, weight-based dosing of ribavirin offered a significant advantage in efficacy of treatment fo
'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Hypertension lowered by Bedtime Dosing
2. Researchers chides parents for overdosing their kids
3. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
4. Collagen improves voice quality in Parkinsonism
5. Breakfast improves memory
6. A new hearing device improves hearing
7. Hormone replacement therapy improves sexual function
8. New therapy improves quality of life for cancer
9. Adding contrast improves ultrasounds ability to detect prostate cancer
10. Switching drugs regularly improves HIV treatment
11. Sage Improves Memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/19/2014)... 20, 2014 Hastings and Hastings, a ... of service throughout the greater Phoenix area and across ... with regard to catastrophic automobile accidents. Statistics have indicated ... and throughout Arizona. As such, Hastings and Hastings has ... representation for those who have been injured through no ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s ... for long evening dresses . All the company’s ... the current discount is up to 66 percent off. ... in the fashion field. Its dress specialists are striving ... various parts of the world. All the company’s items ...
(Date:10/19/2014)... that causes inflammation in the spinal joints and ... ancient Egyptian royal families. Now a new study ... journal of the American College of Rheumatology (ACR), ... condition called diffuse idiopathic skeletal hyperostosis (DISH) in ... 20th Dynasties. , Ankylosing spondylitis is a ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... March 17 CUREXO Technology Corporation, pioneer in ... products for orthopaedic applications, which is focused on ... they received the NSAI (National Standards of Ireland) ... I.S. EN ISO 13485:2003.CUREXO Technology Company has been ...
... 17 FRIED LICE: "You don,t have to be such a ... manufacturing company, is set to introduce the latest in delousing technology. ... Disease Control "CDC" website. The guidelines are clear in stating: "to ... of 130 degrees." Lice Safe was able to adapt a ...
... finds, , , TUESDAY, March 17 (HealthDay News) -- ... that black male children may have a greater risk ... survey included 8,203 people, from infants to seniors who ... issues with eggs, milk, peanuts and shrimp. The ...
... awarded a project to provide interactive, high-quality medical video for 28 ... will be demonstrating the solutions being implemented at WFUBMC at the ... West Building, Chicago, Illinois. Rivulet is in Booth #2428. , ... ...
... - New $2.1 Million SBIR Grant Extends NHGRI ... Whole Genome Imaging and Analysis Platform -PHILADELPHIA, March ... nanoscale platforms for biomedical research, molecular diagnostics and ... II grant from the National Human Genome Research ...
... Germgard Lighting LLC, a New Jersey-based, early-phase ... revolutionary, ultra-fast, bare-hand sanitation capability. Germgard,s technology will ... by curtailing infections resulting from stays in hospitals.Hospital ... their families, and undermines the financial well-being of ...
Cached Medicine News:Health News:CUREXO Technology Corporation Receives Quality Certificate 2Health News:Lice Safe Introduces Licen Tool 2Health News:Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video 2Health News:Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video 3Health News:BioNanomatrix Awarded Phase II NIH Grant to Support Development of Its Single-Molecule Nanoscale Whole Genome Analyzer 2Health News:Disruptive Hand Sanitation Product to Save Healthcare Industry Billions 2
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... 17, 2014 ... announced the addition of the  "China Interventional ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... China impacted by ... consumption concept, dietary habit, way of working ...
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... Disease Indication for HUMIRA Provides Patients with Visible, ... Chronic Autoimmune Disease, ABBOTT PARK, Ill., Jan. ... it has received U.S. Food and Drug Administration ... for adult patients,with moderate to severe chronic plaque ...
... Jan. 17 GeoVax Labs, Inc. (OTC,Bulletin Board: ... it has been named a "2008 Deal of ... recognized GeoVax for receiving a,$15 million IPCAVD (Integrated ... of Health (NIH) in October,2007. The award will ...
Cached Medicine Technology:Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 3Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 4Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 5Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 6Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 7GeoVax Labs, Inc. Selected by Georgia Bio as '2008 Deal of the Year' Award Winner in Life Sciences Industry 2GeoVax Labs, Inc. Selected by Georgia Bio as '2008 Deal of the Year' Award Winner in Life Sciences Industry 3GeoVax Labs, Inc. Selected by Georgia Bio as '2008 Deal of the Year' Award Winner in Life Sciences Industry 4
... Para 5X is a whole blood hematology ... 60C+, 80 and 120, and the Coulter ... offers a unique white cell differential, positioning ... algorithms on the systems. The product offers ...
... blood assayed hematology control, offers complete assay ... available with the Coulter GENS, STKS, MAXM ... open-vial stability, 105-day closed-vial stability and is ... The 4.0ml pierceable cap vial is compatible ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: